Content related to NANT Pediatric Cancer Consortium Spearheads Bench-to-Bedside Research to Identify Safe and Effective Therapy for a Type of High-Risk Neuroblastoma

Study shows that combining MIBG therapy with immunotherapy and vorinostat may boost response rates in patients with relapsed neuroblastoma.

A statistical analysis of the largest study cohort to date sheds light on improvements—and gaps—in post-relapse treatment for Acute Lymphoblastic Leukemia.

A CHLA oncologist is leading new research to improve outcomes for children, adolescents and young adults with relapsed or treatment-resistant germ cell tumors.

The trial is studying a potential treatment for Dup15q and incorporates an EEG biomarker established by CHLA researchers.

A CHLA neuro-oncologist shares how using real-world data could make clinical trials more feasible for rare childhood brain tumors.

A CHLA clinical trial finds that N-acetylcysteine may be a promising next-generation therapy to reduce the risk of cisplatin-induced hearing loss.

Marilyn Smith became a prolific donor in hopes of helping more young cancer patients reach the same positive outcome as her granddaughter.

Children’s Hospital Los Angeles researchers develop a pediatric solid tumor liquid biopsy for use when obtaining a tissue biopsy is not feasible.

Four investigators share their research—and how the USC/CHLA facility will help bring novel cell therapies to clinical trials faster.